Last reviewed · How we verify

inhaled nitric oxide

Stony Brook University · FDA-approved active Small molecule Quality 5/100

inhaled nitric oxide is a Small molecule drug developed by Stony Brook University. It is currently FDA-approved. Also known as: GeNOsyl(R) Delivery System, GeNOsyl(R) Acute DS, INO, standard respiratory therapy vs iNO.

At a glance

Generic nameinhaled nitric oxide
Also known asGeNOsyl(R) Delivery System, GeNOsyl(R) Acute DS, INO, standard respiratory therapy vs iNO, iNO
SponsorStony Brook University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about inhaled nitric oxide

What is inhaled nitric oxide?

inhaled nitric oxide is a Small molecule drug developed by Stony Brook University.

Who makes inhaled nitric oxide?

inhaled nitric oxide is developed and marketed by Stony Brook University (see full Stony Brook University pipeline at /company/stony-brook-university).

Is inhaled nitric oxide also known as anything else?

inhaled nitric oxide is also known as GeNOsyl(R) Delivery System, GeNOsyl(R) Acute DS, INO, standard respiratory therapy vs iNO, iNO.

What development phase is inhaled nitric oxide in?

inhaled nitric oxide is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing